SMI Ends Week Higher as Pharma Giants Drive Recovery
The Swiss Market Index (SMI) closed the week up 0.5 percent at 14,456.98 points, recovering from earlier losses driven by a late-session rally in heavyweights Roche and Novartis, according to market data reported by finanzen.ch and Finanz und Wirtschaft. The late rebound helped offset broader headwinds, including geopolitical tensions and shifting sentiment across European equities.
Pharma Heavyweights Reverse Early Session Losses
The path to the weekly gain was far from linear. Trading kicked off on a soft note ahead of a Verfallstermin. According to reporting by finanzen.ch, the SMI dropped toward an intraday low of roughly 14,280 points before staging a sharp afternoon reversal. The benchmark index swung over 190 points to hit a high of 14,474 before settling up 0.62 percent on the final trading session of the week.
The recovery rested squarely on the shoulders of Switzerland’s pharmaceutical anchors. Roche gained 1.0 percent by the closing bell, while rival Novartis advanced 0.9 percent. Both firms erased steep intraday deficits to cap off a strong week, outperforming expectations after notes from Migros Bank highlighted both drugmakers as beneficiaries of an expanded free trade framework with China. Richemont also climbed 1.5 percent, riding optimism over international demand dynamics.
Cyclical and construction-related equities reinforced the afternoon upswing. Kühne+Nagel led blue-chip gainers with a 2.8 percent surge, while Geberit added 1.4 percent and Sika moved up 1.0 percent. Holcim climbed 0.9 percent, bolstered by market reception of its recent 840 million euro acquisition of German firm Fermacell, as reported by finanzen.ch.
Weaker Performers Drag on the Wider Index
Not all sectors shared in the Friday relief rally.
Swisscom slipped 0.9 percent, followed by Alcon with a 0.8 percent loss. UBS shed 0.5 percent. Modest pullbacks also hit Swiss Life and Partners Group. Within the broader market segment, Straumann dropped 3.3 percent after receiving a rating downgrade from Deutsche Bank, moving from buy down to hold, according to finanzen.ch records. Conversely, Georg Fischer jumped 3.3 percent after Research Partners upgraded the stock from hold to buy, capturing the top spot in the mid-cap SMIM index, which finished the session up 0.55 percent at 3,157.21 points.
Macroeconomic Pressures and Divergent Analyst Outlooks
Underpinning the choppy trading sessions is a complex macro matrix featuring high oil prices and lingering geopolitical uncertainty in the Middle East. According to coverage from finanzen.ch, Brent crude held steady near 94 US dollars per barrel amid statements from US President Donald Trump regarding economic pressure on Iran, contrasting with levels under 80 dollars earlier in the month.
Market sentiment remains divided regarding the durability of the equity rally. Citing an assessment from the investment office of UBS, market reports point to a baseline positive scenario predicated on resilient artificial intelligence spending, stable corporate earnings growth, and easing inflationary pressures. Simultaneously, cautious commentary highlights thin summer liquidity and high historical valuations as ongoing structural risks for passive index trackers.
The broader Swiss Performance Index (SPI) tracked the primary benchmark upward, closing the session 0.59 percent higher at 20,317.78 points.